| アブストラクト | Real-world evidence for clinical outcomes and treatment patterns in patients with hormone receptor-positive(HR+)and human epidermal growth factor receptor 2-negative(HER2-)early breast cancer(EBC)in Japan is limited. We aimed to provide recent evidence in this population using the National Database of Health Insurance Claims and Specific Health Check-ups of Japan(NDB). Adults >/=20 years old who were diagnosed with HR+/HER2- breast cancer and underwent breast resection surgery were followed up. Patient characteristics and treatment patterns were evaluated. Durations of overall post-operative endocrine therapy(ET)and luteinizing hormone-releasing hormone(LH-RH)agonist therapy, and time to metastasis/recurrence after surgery were analyzed using Kaplan-Meier method. Overall, 294,904 patients were included. Cyclophosphamide and tamoxifen were the most common peri-operative chemotherapeutic and ET drugs. Median(95% confidence interval[CI])duration of post-operative ET and LH-RH agonist therapy was 5.01(5.01-5.01)years and 2.13 (2.12-2.14)years, respectively. Five-year cumulative rate(95% CI)of any recurrence was 8.6%(8.5-8.7), visceral metastasis being the most common. Nation-wide treatment patterns were described, which were consistent with guideline recommendations for patients with HR+, HER2- EBC. Further discussion is required to delay metastasis/recurrence and improve clinical outcomes(Fig. 1: Plain language summary of the study). |
|---|
| ジャーナル名 | Gan to kagaku ryoho. Cancer & chemotherapy |
|---|
| Pubmed追加日 | 2024/1/22 |
|---|
| 投稿者 | Komatsu, Shuichiro; Kawai, Masaaki; Takada, Masahiro; Nakayama, Takahiro; Masuda, Norikazu; Shiheido, Hirokazu; Cai, Zhihong; Huang, Yu Jing; Kawaguchi, Tsutomu; Tanizawa, Yoshinori |
|---|
| 組織名 | Public Welfare IT Services Division, NTT DATA Corporation.;Dept. of Surgery I, Yamagata University Graduate School of Medical Science;Dept. of Breast Surgery, Kyoto University Graduate School of Medicine;Dept. of Breast and Endocrine Surgery, Osaka International Cancer Institute;Dept. of Breast and Endocrine Surgery, Nagoya University Graduate School of;Medicine;Japan Drug Development & Medical Affairs, Eli Lilly Japan K. K.;Eli Lilly and Company |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38247066/ |
|---|
